Venous thromboembolism prevention with low molecular weight heparin may reduce hemorrhagic transformation in acute ischemic stroke
ConclusionsThis retrospective study suggests that SHPD may play a protective role in HT appearance and evolution, which requires verification by a randomized clinical trial. (Source: Neurological Sciences)
Source: Neurological Sciences - March 24, 2020 Category: Neurology Source Type: research

In Vitro Demonstration of Drug-Reagent Interactions Among Commonly Used Parenteral Drugs in Cardiology.
CONCLUSION: Parenteral drugs used in cardiology can significantly interfere with troponin I, CK-MB mass, Nt-proBNP, and D-dimer tests in the analytical phase because of drug-reagent interactions. Minimal deviations in the CK, AST, and LDH tests were observed using spectrophotometric methods. Thus, changes in test results may be due to drug interference rather than the treatment itself. Clinicians should consider the possibility of drug interference in cases of doubtful cardiac test results that do not comply with the diagnosis. PMID: 32101135 [PubMed - as supplied by publisher] (Source: Cardiovascular and Hematological...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - February 28, 2020 Category: Cardiology Tags: Cardiovasc Hematol Agents Med Chem Source Type: research

Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Abstract DS-1040, a novel low-molecular-weight inhibitor of activated thrombin-activatable fibrinolysis inhibitor, is under development for the treatment of thromboembolic diseases including venous thromboembolism and acute ischemic stroke. Here we describe the results of 3 studies that evaluated the safety and tolerability of DS-1040 along with the effect on DS-1040 pharmacokinetic (PK) parameters, when dosed alone or when coadministered with aspirin (NCT02071004), clopidogrel (NCT02560688), or enoxaparin in healthy subjects. Concomitant administration of single-dose DS-1040 with multiple-dose aspirin, multiple-d...
Source: The Journal of Clinical Pharmacology - February 27, 2020 Category: Drugs & Pharmacology Authors: Limsakun T, Dishy V, Mendell J, Pizzagalli F, Pav J, Kochan J, Vandell AG, Rambaran C, Kobayashi F, Orihashi Y, Warren V, McPhillips P, Zhou J Tags: J Clin Pharmacol Source Type: research

4:12 PM Abstract No. 281 Short dwell time ( < 30 day) inpatient retrievable inferior vena cava filters for averting pulmonary embolism in trauma
This study evaluates our experience with successful same-admission retrieval and rate of averted PE. (Source: Journal of Vascular and Interventional Radiology : JVIR)
Source: Journal of Vascular and Interventional Radiology : JVIR - February 20, 2020 Category: Radiology Authors: M. Sohner, S. Prisacaru, P. Habibollahi, P. Sutphin, A. Pillai, M. Kolber Tags: Scientific Session 30 Source Type: research

Changes in serum D-dimer level and effect of enoxaparin sodium after a cesarean section: a retrospective study
. (Source: Journal of Maternal-Fetal and Neonatal Medicine)
Source: Journal of Maternal-Fetal and Neonatal Medicine - February 12, 2020 Category: Perinatology & Neonatology Authors: Keisuke Miyamoto Hiroaki Komatsu Yohei Nagaya Satoru Tsukihara Masako Sarugami Daiken Osaku Fuminori Taniguchi Tasuku Harada Yasunobu Kanamori Source Type: research

Fixed or weight-tiered enoxaparin after thoracic surgery for venous thromboembolism prevention
Publication date: Available online 8 February 2020Source: The Annals of Thoracic SurgeryAuthor(s): Christopher J. Pannucci, Kory I. Fleming, Corinne Bertolaccini, Lauren Moulton, John Stringham, Shari Barnett, Jules Lin, Thomas K. VargheseAbstractBackgroundVenous thromboembolism is an important patient safety issue in thoracic surgery patients. The optimal enoxaparin dose remains unclear. This multicenter pre/post clinical trial compared the pharmacokinetics of fixed versus weight-tiered enoxaparin, and their impact on 90-day venous thromboembolism and bleeding.MethodsThoracic surgery patients were prospectively enrolled u...
Source: The Annals of Thoracic Surgery - February 9, 2020 Category: Cardiovascular & Thoracic Surgery Source Type: research

Plasma levels of enoxaparin oligosaccharides, antifactor-Xa and thrombin generation in patients undergoing haemodialysis
Low molecular weight heparins are used during haemodialysis for thromboprophylaxis of the dialysis circuit, with plasma antifactor-Xa (anti-Xa) activity used as a surrogate measure for effective anticoagulation. However, this pharmacokinetic parameter does not always correlate with pharmacodynamic effects in patients. The aim of this study was to investigate the relationship between actual plasma levels of the low molecular weight heparins enoxaparin, anti-Xa activity, and global coagulation measurement of thrombin generation during haemodialysis. Blood was analysed from 16 adult patients with end-stage kidney disease at 0...
Source: Blood Coagulation and Fibrinolysis - February 8, 2020 Category: Hematology Tags: ORIGINAL ARTICLES Source Type: research

Heparin challenge test in patients undergoing cardiac surgery: dealing with heparin allergy
A history of heparin hypersensitivity in patients undergoing cardiopulmonary bypass surgery poses the dilemma of which anticoagulant to use. Here, we report the successful use of a heparin challenge test in a 66-year-old female candidate for coronary artery bypass graft surgery with a past medical history of enoxaparin type I hypersensitivity after pulmonary embolism. Challenge and desensitization protocols are effectively used for essential antibiotics in patients with severe infections and/or allergies, or patients with aspirin intolerance requiring revascularization for coronary disease. A successful use of desensitizat...
Source: Blood Coagulation and Fibrinolysis - February 8, 2020 Category: Hematology Tags: CASE REPORTS Source Type: research

Fixed or weight-tiered enoxaparin after thoracic surgery for venous thromboembolism prevention.
Abstract BACKGROUND: Venous thromboembolism is an important patient safety issue in thoracic surgery patients. The optimal enoxaparin dose remains unclear. This multicenter pre/post clinical trial compared the pharmacokinetics of fixed versus weight-tiered enoxaparin, and their impact on 90-day venous thromboembolism and bleeding. METHODS: Thoracic surgery patients were prospectively enrolled using a pre/post study design Cohort 1 received enoxaparin 40mg daily, and Cohort 2 received a weight-tiered regimen (
Source: The Annals of Thoracic Surgery - February 8, 2020 Category: Cardiovascular & Thoracic Surgery Authors: Pannucci CJ, Fleming KI, Bertolaccini C, Moulton L, Stringham J, Barnett S, Lin J, Varghese TK Tags: Ann Thorac Surg Source Type: research

Prophylaxis for Pediatric Venous Thromboembolism: Current Status and Changes Across Pediatric Orthopaedic Society of North America From 2011.
Authors: Murphy RF, Williams D, Hogue GD, Spence DD, Epps H, Chambers HG, Shore BJ Abstract INTRODUCTION: Pediatric venous thromboembolism (VTE) is a concern for orthopaedic surgeons. We sought to query the Pediatric Orthopaedic Society of North America (POSNA) members on current VTE prophylaxis practice and compare those results with those of a previous survey (2011). METHODS: A 35-question survey was emailed to all active and candidate POSNA members. The survey consisted of questions on personal and practice demographics; knowledge and implementation of various VTE prophylaxis protocols, mechanical and chemic...
Source: The Journal of the American Academy of Orthopaedic Surgeons - February 7, 2020 Category: Orthopaedics Tags: J Am Acad Orthop Surg Source Type: research

Response to Comment on: “Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study”
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - February 3, 2020 Category: Drugs & Pharmacology Source Type: research

Comment On: “Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study”
(Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - February 3, 2020 Category: Drugs & Pharmacology Source Type: research

Permeation-Enhancing Nanoparticle Formulation to Enable Oral Absorption of Enoxaparin.
This study tests the hypothesis that association complexes formed between enoxaparin and cetyltrimethylammonium bromide (CTAB) augment permeation across the gastrointestinal mucosa due to improved encapsulation of this hydrophilic macromolecule within biocompatible poly (lactide-co-glycolide, PLGA RG 503) nanoparticles. When compared with free enoxaparin, association with CTAB increased drug encapsulation efficiency within PLGA nanoparticles from 40.3 ± 3.4 to 99.1 ± 1.0%. Drug release from enoxaparin/CTAB PLGA nanoparticles was assessed in HBSS, pH 7.4 and FASSIFV2, pH 6...
Source: AAPS PharmSciTech - February 3, 2020 Category: Drugs & Pharmacology Authors: Eleraky NE, Swarnakar NK, Mohamed DF, Attia MA, Pauletti GM Tags: AAPS PharmSciTech Source Type: research

Venous thromboembolism prophylaxis in patients hospitalized in medical wards: A real life experience
The objective of the study was to evaluate the rate of VTE risk assessment in routine medical department practice, the rate of eligible patients for thromboprophylaxis, the rate of patients who received thromboprophylaxis, and their outcome. Medical records of consecutive patients (3000 at 2013, 1000 at 2018) hospitalized in medical department were reviewed, retrospectively, for demographic, clinical characteristics, thromboprophylaxis treatment with enoxaparin and outcome (up to 90 days following discharge). Padua score was used for VTE risk assessment. VTE diagnosis was based on clinical suspicion. The mean patient's a...
Source: Medicine - February 1, 2020 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

[Hemorrhagic bullous dermatosis (HBD): A rare side-effect of heparins].
CONCLUSION: Heparin-induced BHD is a rare but benign side effect of heparins. In the absence of recommendations, therapeutic management should be adapted to the individual situation. PMID: 32005507 [PubMed - as supplied by publisher] (Source: Annales de Dermatologie et de Cenereologie)
Source: Annales de Dermatologie et de Cenereologie - January 28, 2020 Category: Dermatology Authors: Gérard A, Levavasseur M, Gaboriau L, Stichelbout M, Staumont-Salle D Tags: Ann Dermatol Venereol Source Type: research

Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.
CONCLUSION: This population-based analysis of patients with VTE extends results of randomized clinical trials indicating lower risks of development of recurrent VTE and major bleeding events with use of apixaban versus warfarin in real-world settings. The observed benefits of apixaban extended to selected subgroups of the VTE population, including patients with provoked VTE. PMID: 31974557 [PubMed - in process] (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - January 24, 2020 Category: Drugs & Pharmacology Authors: Dawwas GK, Smith SM, Dietrich E, Lo-Ciganic WH, Park H Tags: Am J Health Syst Pharm Source Type: research

Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials.
Abstract Patients with renal impairment are at higher risk of thrombosis and bleeding than those with normal renal function. The optimal rivaroxaban dose for thromboprophylaxis in acutely ill medical patients with renal impairment is unknown. MARINER and MAGELLAN were multicenter, randomized clinical trials of rivaroxaban in acutely ill medical patients. Efficacy and safety outcomes in patients with renal impairment in MARINER (7.5 mg once daily) were compared with those in patients with normal renal function in MARINER (10 mg once daily) and in a subpopulation of MAGELLAN that excluded patients at h...
Source: Thrombosis and Haemostasis - January 23, 2020 Category: Hematology Authors: Weitz JI, Raskob GE, Spyropoulos AC, Spiro TE, De Sanctis Y, Xu J, Lu W, Suh E, Argenti D, Yang H, Albanese J, Lipardi C, Barnathan ES Tags: Thromb Haemost Source Type: research

Supplementation with antithrombin III ex vivo optimizes enoxaparin responses in critically injured patients
The high incidence of venous thromboembolism (VTE) following trauma persists in spite of aggressive thromboprophylaxis strategies. Approximately half of VTE patients do not achieve the recommended anti-FXa response to enoxaparin anticoagulation (0.1 –0.4 IU/mL), however, research to explain or correct this phenomenon is lacking. We hypothesized that antithrombin III (AT) deficiency is associated with poor enoxaparin responsiveness in trauma patients that develop VTE which can be reversed through supplementation with AT. (Source: Thrombosis Research)
Source: Thrombosis Research - January 15, 2020 Category: Hematology Authors: Jessica C. Cardenas, Yao-Wei Wang, Jay V. Karri, Seenya Vincent, Andrew P. Cap, Bryan A. Cotton, Charles E. Wade Tags: Full Length Article Source Type: research

Effect of Osocimab on Venous Thromboembolism Prevention Among Patients Undergoing Knee Arthroplasty
This phase 2 clinical noninferiority trial compared 4 doses of postoperative osocimab, a monoclonal antibody against factor XI, vs enoxaparin and apixiban on venous thromboembolism incidence among patients undergoing knee replacement. (Source: JAMA)
Source: JAMA - January 14, 2020 Category: General Medicine Source Type: research

Enoxaparin induced eruptive angiokeratoma, an extremely rare side effect
AbstractEnoxaparin is one of the most commonly used anticoagulants in the management of thromboembolic events. Herein we report a unique case of enoxaparin induced eruptive angiokeratomas in a patient with a history of ischemic cardiomyopathy who presented with acute decompensated heart failure and a new-onset generalized skin rash that bleeds on trauma, suggestive of angiokeratomas. Dermoscopic examination, as well as skin biopsy, were done upon clinical suspicion of eruptive angiokeratomas, to confirm the diagnosis. Dermoscopy showed dark lacunae surrounded by erythema, while skin biopsy revealed dilated congested capill...
Source: Journal of Thrombosis and Thrombolysis - January 10, 2020 Category: Hematology Source Type: research

Edoxaban versus warfarin in vitamin K antagonist experienced and na ïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial
ConclusionsEdoxaban had comparable efficacy and safety to optimized anticoagulation with enox –warf. The primary efficacy and safety endpoint outcomes were broadly similar between VKA experienced or naïve patients. (Source: Clinical Research in Cardiology)
Source: Clinical Research in Cardiology - January 8, 2020 Category: Cardiology Source Type: research

An obscure case of using apixaban anti-Xa levels in a morbidly obese patient who was nil per os with enterocutaneous fistula
Apixaban anti-Xa levels have been introduced to monitor apixaban activity. Presented is a fundamental use of anti-Xa monitoring in questionable absorption in enterocutaneous fistula. A 57-year-old morbidly obese male (150 kg, BMI 42.5) presented to the emergency department with deep venous thromboses and pulmonary embolisms. He also had high-output enterocutaneous fistula managed with an abdominal collection device, total parental nutrition therapy, and nil per os status. He was able to take some oral (PO) medications; however, he reported finding whole capsules in his collection device. He refused enoxaparin injections ...
Source: Blood Coagulation and Fibrinolysis - January 1, 2020 Category: Hematology Tags: CASE REPORTS Source Type: research

Successful Long ‐term Anticoagulation with Enoxaparin in a Patient with a Mechanical Heart Valve
We report a case of successful long‐term anticoagulation with enoxaparin in a patient with a mechanical aortic valve who had a contraindication to warfarin. The patient developed a left thigh hematoma requiring surgical evacuation one month after initiation of weight‐based dosing of e noxaparin. His dose was then titrated based on peak anti–Xa levels (goal 0.6–1.0 IU/mL). He remained free of signs and symptoms of thromboembolic events, valve dysfunction, bleeding complications, or major adverse effects from long‐term enoxaparin use for the next 13 years. Our case provides p romising evidence of the potent...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - December 29, 2019 Category: Drugs & Pharmacology Authors: Xin Wang, Carol Mathew, Sowmya Korapati, Venu G. Bathini Tags: CASE REPORT Source Type: research

Randomized Trial of Deep Vein Thrombosis Chemoprophylaxis with Bemiparin and Enoxaparin in Patients with Moderate to High Thrombogenic Risk Undergoing Plastic and Reconstructive Surgery Procedures
ConclusionsDVT was prevented with bemiparin, without significant bleeding increase nor adverse events; moreover, the cost of bemiparin is lower than enoxaparin. Bemiparin can be considered as alternative drug for DVT chemoprophylaxis in PRSx procedures.Level of Evidence IIIThis journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authorswww.springer.com/00266. (Source: Aesthetic Plastic Surgery)
Source: Aesthetic Plastic Surgery - December 18, 2019 Category: Cosmetic Surgery Source Type: research

Safety and efficacy of high-dose unfractionated heparin versus high-dose enoxaparin for venous thromboembolism prevention in morbidly obese hospitalized patients
Venous thromboembolism is a cause of morbidity and mortality in hospitalized patients, and morbid obesity increases this risk. Various prophylaxis dosing strategies have been investigated. However, it is unclear if high-fixed dose enoxaparin or high-fixed dose unfractionated heparin thromboprophylaxis is optimal for minimizing the incidence of major bleeding and reducing hospital-acquired venous thromboembolism. (Source: The American Journal of Medicine)
Source: The American Journal of Medicine - December 17, 2019 Category: General Medicine Authors: S. Walker Mason, Alexandra Barber, Emily Jones, Sheh-Li Chen, Stephan Moll, Kalynn Rohde Tags: Clinical Research Study Source Type: research

Prophylactic Enoxaparin Adjusted by Anti-Factor Xa Peak Levels Compared with Recommended Thromboprophylaxis and Rates of Clinically Evident Venous Thromboembolism in Surgical Oncology Patients
Enoxaparin 40 mg daily is often associated with subprophylactic peak anti-Xa levels in surgical oncology patients. Dose adjustment based on anti-Xa levels resulted in a lower rate of in-hospital venous thromboembolism without increased risk of bleeding. (Source: Journal of the American College of Surgeons)
Source: Journal of the American College of Surgeons - December 13, 2019 Category: Surgery Authors: Katherine Kramme, Paya Sarraf, Gitonga Munene Tags: Original Scientific Article Source Type: research

Prevention of Postoperative Abdominal Adhesions Using Systemic Enoxaparin and Local Diclofenac. An Experimental Study
The objective of this study was to test the potential benefits of the use of subcutaneous enoxaparin plus intraperitoneal diclofenac in a porcine model.Material and MethodsUsing 32 hybrid female pigs, surgical adhesions were induced by open conventional splenectomy. The animals were divided into 4 groups: I) control, irrigation with saline solution; II) subcutaneous Enoxaparine was applied, III) intraperitoneal Diclofenac and IV) Combination of both.ResultsBy far, the greater degree of formation of abdominal adhesions occurs in the non ‐treated control group I (p
Source: Surgical Practice - December 13, 2019 Category: Surgery Authors: Gilberto Guzm án‐Valdivia Gómez, Eduardo Linares‐Rivera, Eduardo Tena‐Betancourt, Gerardo Arroyo‐Del Castillo, Lukas Reipen Tags: Original Article Source Type: research

Venous thrombosis after nitrous oxide abuse, a case report
We present a 21-year-old female with no medical history who presented to the emergency department for confusion, hallucinations, weakness, and falls. She was accompanied by her roommates, who endorsed significant nitrous oxide abuse. Imaging revealed a large cerebral sinus venous thr ombus with extension into the transverse sinus, sigmoid sinus and internal jugular vein. She had no prior history of venous or arterial thrombosis. Hypercoagulability workup demonstrated an elevated homocysteine level, elevated methylmalonic acid level, and normal cobalamin and folate levels. Additi onally, she was found to be 11 weeks pr...
Source: Journal of Thrombosis and Thrombolysis - December 9, 2019 Category: Hematology Source Type: research

Extended thromboprophylaxis for hip or knee arthroplasty. Does the administration route and dosage regimen affect adherence? A cohort study
ConclusionsThe number of daily doses prescribed was related to adherence to extended chemical prophylaxis, while the route of administration did not seem to have a significant impact. Strategies to promote outpatient compliance must be implemented, especially when regimes including more than one daily dose are prescribed. (Source: International Orthopaedics)
Source: International Orthopaedics - December 6, 2019 Category: Orthopaedics Source Type: research

Heparin hemorrhagic bullae induced by enoxaparin.
Authors: Torres-Navarro I, de Unamuno-Bustos B, Pujol-Marco C PMID: 31784110 [PubMed - as supplied by publisher] (Source: Medicina Clinica)
Source: Medicina Clinica - December 2, 2019 Category: General Medicine Tags: Med Clin (Barc) Source Type: research

Comparison of Efficacy and Safety of Two Different Enoxaparin Products in Prevention of Venous ...
Venous thromboembolism (VTE) occurs in about 5 percent of patients undergoing major abdominal surgeries. Prophylaxis of VTE is recommended using unfractionated heparin (UF) or low molecular weight heparin (LMWH) in high-risk patients. In spite of advantages and confirmed cost-effectiveness of LMWH, high costs of enoxaparin branded preparations limit its use. We aimed to compare the efficacy and safety of two enoxaparin preparations. In this open-label randomized clinical trial, 200 patients were recruited to recieve PDxane® or Clexane®, 40 mg subcutaneously daily, from the day of surgery for 10 days. The patients w...
Source: Iranian Journal of Pharmaceutical Research - November 30, 2019 Category: Drugs & Pharmacology Source Type: research

A Caprini Risk Score-Based Cost-Effectiveness Analysis of Enoxaparin for the Thromboprophylaxis of Patients After Nonorthopedic Surgery in a Chinese Healthcare Setting
ConclusionsAs the first analysis evaluating the economic outcomes of enoxaparin in patients undergoing general non-orthopedic surgery, this study suggests that thromboprophylaxis with enoxaparin is highly cost-effective compared with no prevention in patients with Caprini risk score  ≥ 3. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - November 26, 2019 Category: Drugs & Pharmacology Source Type: research

Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial
ConclusionsDTI and anti-Xa drugs exert opposite effects on platelet function. A significant decrease in platelet activation through COX1 (also known as prostaglandin G/H synthase  1) was observed with enoxaparin, but no significant differences in platelet function were observed with dabigatran.Trial RegistrationClinicalTrials.gov identifier, NCT02389582. (Source: Advances in Therapy)
Source: Advances in Therapy - November 22, 2019 Category: Drugs & Pharmacology Source Type: research

Differential effects of direct factor IIa and factor Xa inhibitors in protein C-deficient plasma detected using thrombin generation and viscoelastometry assays.
CONCLUSION: The selective direct FXa and FIIa inhibitors at high concentrations both counteracted the abnormal thrombin generation and clot formation observed in PC-deficient plasma, but with qualitative differences in their effects. PMID: 31756037 [PubMed - as supplied by publisher] (Source: International Journal of Laboratory Hematology)
Source: International Journal of Laboratory Hematology - November 22, 2019 Category: Hematology Authors: Aungraheeta R, FitzGibbon L, Reilly-Stitt C, Mumford AD Tags: Int J Lab Hematol Source Type: research

Effectiveness of the tromboembolic venous disease treatments estimated through clinical trials vs. observational studies
Conclusions: observational studies that use propensity analysis and CSs find similar results regarding the effect of VTE treatments, although there are occasionally differences in the direction/magnitude of this effect. (Source: European Respiratory Journal)
Source: European Respiratory Journal - November 21, 2019 Category: Respiratory Medicine Authors: Barbero Herranz, E., Coscia, C., Jaureguizar, A., Quezada, C. A., Muriel, A., Monreal, M., Villen, T., Chiluiza, D., Yusen, J., Jimenez, D. Tags: Pulmonary embolism Source Type: research

Portal Vein Thrombosis After Total Pancreatectomy and Islet Autotransplant: Prophylaxis and Graft Impact
Conclusions There was no difference between enoxaparin or UFH prophylaxis in preventing PVT, but there may be a higher incidence of other thrombotic complications with enoxaparin. In the setting of routine screening and anticoagulation therapy, PVT is a self-limited process. (Source: Pancreas)
Source: Pancreas - November 1, 2019 Category: Gastroenterology Tags: Original Articles Source Type: research

Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban.
This study aimed to compare the prevalence of PTS and RVT, in patients with previous DVT treated with rivaroxaban or enoxaparin/warfarin. A total of 129 patients with previous proximal lower limb DVT and treated with rivaroxaban (n = 71) or enoxaparin/warfarin (n = 58) for at least 3 months were included. The Villalta scale for PTS was performed after treatment. The median duration of the DVT symptoms before anticoagulation was 7 days for both groups. The rate of PTS was 50.7% in the patients treated with rivaroxaban and 69% in the enoxaparin/warfarin group. Enoxaparin/warfarin showed an increased prevalence of...
Source: Vascular Pharmacology - October 30, 2019 Category: Drugs & Pharmacology Authors: Ferreira T, Huber SC, de Moraes Martinelli B, Junior AL, Menezes FH, Orsi FA, Bittar LF, de Oliveira LFG, Sodre LR, Mello TT, Rielli G, Colella MP, de Paula EV, Yamaguti-Hayakawa GG, Montalvão S, Annichino-Bizzacchi JM Tags: Vascul Pharmacol Source Type: research

Comparison of Efficacy and Safety of Two Different Enoxaparin Products in Prevention of Venous ...
Venous thromboembolism (VTE) occurs in about 5 percent of patients undergoing major abdominal surgeries. Prophylaxis of VTE is recommended using unfractionated heparin (UF) or low molecular weight heparin (LMWH) in high-risk patients. In spite of advantages and confirmed cost-effectiveness of LMWH, high costs of enoxaparin branded preparations limit its use. We aimed to compare the efficacy and safety of two enoxaparin preparations. In this open-label randomized clinical trial, 200 patients were recruited to recieve PDxane® or Clexane®, 40 mg subcutaneously daily, from the day of surgery for 10 days. The patients w...
Source: Iranian Journal of Pharmaceutical Research - October 27, 2019 Category: Drugs & Pharmacology Source Type: research

The ATLANTIC study: AnTi-Xa Level Assessment iN Trauma Intensive Care
To quantify the pharmacodynamic (PD) activity of daily subcutaneous (SC) enoxaparin as venous thromboembolism (VTE) prophylaxis in high-risk trauma patients admitted to the intensive care unit (ICU). (Source: Injury)
Source: Injury - October 26, 2019 Category: Orthopaedics Authors: Sandeep Rakhra, Emma-Leah Martin, Mark Fitzgerald, Andrew Udy Source Type: research

Evaluation of the Efficacy of Enoxaparin in the Neonatal Intensive Care Unit
This article evaluates the efficacy of enoxaparin when targeting anti-factor Xa levels of 0.5 to 1 units per milliliter in the neonatal intensive care unit. Study Design This is a retrospective chart review of 45 neonates receiving enoxaparin for the treatment of venous thromboembolism. Enoxaparin dosing and corresponding anti-factor Xa levels were collected. Time to resolution of clot was confirmed by imaging and compared between clots in various locations. Results The median time to clot resolution was 76 days (interquartile range 40–91 days). Clot location, postnatal age, and sex at the clot onset ...
Source: American Journal of Perinatology - October 26, 2019 Category: Perinatology & Neonatology Authors: Song, Diane Magers, Jacqueline Abdel-Rasoul, Mahmoud Prusakov, Pavel Tags: Original Article Source Type: research

Underdosing of Prophylactic Enoxaparin Is Common in Orthopaedic Trauma and Predicts 90-Day Venous Thromboembolism
Objectives: To determine the feasibility and impact of real-time anti-factor Xa (aFXa) level monitoring and enoxaparin dose adjustment in orthopaedic trauma. To examine the adequacy of standard fixed-dose enoxaparin chemoprophylaxis and to examine whether patient-specific factors influence enoxaparin metabolism. Design: Prospective cohort. Setting: Academic Level-I trauma center. Patients: Postoperative adult orthopaedic trauma patients undergoing acute fracture or nonunion surgery of the pelvis, acetabulum, or lower extremity placed on 30 mg of enoxaparin twice daily. Intervention: Peak steady-state aFXa lev...
Source: Journal of Orthopaedic Trauma - October 21, 2019 Category: Orthopaedics Tags: Original Article Source Type: research

Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study
ConclusionStandard dosing of enoxaparin in morbidly obese patients will most likely lead to supratherapeutic anti-Xa levels and thus further investigation is warranted to better determine appropriate dosing. (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - October 17, 2019 Category: Drugs & Pharmacology Source Type: research

Enoxaparin-induced bullous haemorrhagic dermatosis.
PMID: 31617202 [PubMed - as supplied by publisher] (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - October 16, 2019 Category: Dermatology Authors: Lobo Y, Robertson I, Stewart A, Rowe C Tags: Australas J Dermatol Source Type: research

Venous Thromboembolism in Patients with Liver Cirrhosis: Findings from the RIETE (Registro Informatizado de la Enfermedad TromboEmbolica) Registry
Semin Thromb Hemost DOI: 10.1055/s-0039-1697682Patients with cirrhosis are not only at an increased risk of bleeding but also at risk of venous thromboembolism (VTE). We sought to determine the clinical characteristics, management, and outcomes after VTE in patients with cirrhosis. We used the data from RIETE (Registro Informatizado de la Enfermedad TromboEmbolica), an international registry of patients with VTE, to compare the outcomes in patients with and without cirrhosis. Main outcomes included all-cause mortality, pulmonary embolism (PE)-related mortality, recurrent VTE, and bleeding. Among 43,611 patients with acute ...
Source: Seminars in Thrombosis and Hemostasis - October 15, 2019 Category: Hematology Authors: Bikdeli, Behnood Jim énez, David Garcia-Tsao, Guadalupe Barba, Raquel Font, Carme D íaz-Pedroche, María del Carmen Mazzolai, Lucia Little, Derek Henry Wallace Tufano, Antonella Tafur, Alfonso J. Siegal, Deborah Lip, Gregory Y.H. Monreal, Manuel Tags: Review Article Source Type: research

Neural-respiratory inflammasome axis in traumatic brain injury.
Abstract Traumatic brain injury (TBI) is a leading cause of morbidity and mortality. Approximately 20-25% of TBI subjects develop Acute Lung Injury (ALI), but the pathomechanisms of TBI-induced ALI remain poorly defined. Currently, mechanical ventilation is the only therapeutic intervention for TBI-induced lung injury. Our recent studies have shown that the inflammasome plays an important role in the systemic inflammatory response leading to lung injury-post TBI. Here, we outline the role of the extracellular vesicle (EV)-mediated inflammasome signaling in the etiology of TBI-induced ALI. Furthermore, we evaluate ...
Source: Experimental Neurology - October 15, 2019 Category: Neurology Authors: Kerr N, de Rivero Vaccari JP, Dietrich WD, Keane RW Tags: Exp Neurol Source Type: research

Antithrombotic prescriptions for many general surgery patients significantly increases the likelihood of post-operative bleeding complications
Publication date: Available online 7 October 2019Source: The American Journal of SurgeryAuthor(s): Aaron Lee Wiegmann, Syed I. Khalid, Alison C. Coogan, Thomas Q. Xu, Laura A. DeCesare, Nicholas J. Skertich, Jose Velasco, Jonathan A. MyersAbstractBackgroundThe investigators hypothesized that despite cessation recommendations for peri-operative antithrombotic management in the elective setting, the use of these drugs is likely associated with increased odds for bleeding complications.MethodsHumana® insurance claims (22 million covered lives) from 2007 through 2017 were analyzed. Only patients undergoing elective general...
Source: The American Journal of Surgery - October 11, 2019 Category: Surgery Source Type: research

Investigation of the protective effect of enoxaparin and ticagrelor pretreatment against ischemia-reperfusion injury in rat lung tissue
This study was conducted to reveal the possible protective effects of ticagrelor and enoxaparin pretreatment against ischemia-reperfusion (IR)-induced injury on the lung tissue of a rat model. METHODS Wistar albino rats were randomly divided into 4 groups as follows: group-1 (control-sham), group-2 (control-saline+IR), group-3 (ticagrelor+IR), group-4 (enoxaparin+IR). Before the ischemic period, saline, ticagrelor, and enoxaparin were administered to the 2nd-4th groups, respectively. In these groups, IR injury was induced by clamping the aorta infrarenally for 2 h, followed by 4 h of reperfusion except group-1. After the r...
Source: Revista da Associacao Medica Brasileira - October 11, 2019 Category: General Medicine Source Type: research

Cost-Effectiveness of Extended Thromboprophylaxis in Patients Undergoing Colorectal Surgery from a Canadian Health Care System Perspective
CONCLUSIONS: Despite the rarity of venous thromboembolic events, extended thromboprophylaxis is a cost-effective strategy. See Video Abstract at http://links.lww.com/DCR/A976. COSTO-EFECTIVIDAD DE LA TROMBOPROFILAXIS EXTENDIDA EN PACIENTES SOMETIDOS A CIRUGÍA COLORRECTAL DESDE UNA PERSPECTIVA DEL SISTEMA DE SALUD CANADIENSE: ANTECEDENTES: Cada vez hay más pruebas que apoyen la tromboprofilaxis extendida después de la cirugía colorrectal para minimizar la incidencia de eventos tromboembólicos venosos después del alta hospitalaria. Sin embargo, el número absoluto de even...
Source: Diseases of the Colon and Rectum - October 10, 2019 Category: Gastroenterology Tags: Original Contributions: Socioeconomic Source Type: research

Lemierres Syndrome in Pregnancy Secondary to Retropharyngeal Abscess.
Authors: James J, Thulaseedharan NK, Jayachandran NV, Geetha P Abstract Lemierres syndrome (LS) refers to suppurative thrombophlebitis of internal jugular vein (IJV) secondary to oropharyngeal infection. It is caused by the anaerobic bacteria Fusobacterium necrophorum. Here we report a case of LS secondary to retropharyngeal abscess in a pregnant lady with possible underlying connective tissue disorder. A 19-year old primigravida at 6-weeks of gestation, presented with fever, cough, dyspnea, right sided neck pain and swelling. Imaging showed right lower lobe pneumonia with bilateral pulmonary infiltrates and pleura...
Source: Journal of the Association of Physicians of India - September 29, 2019 Category: General Medicine Tags: J Assoc Physicians India Source Type: research